E

Evolution Research Group | Clinical Pharmacology of Miami

Research site
(Unclaimed)
Location
550 West 84th Street, Miami, Florida, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

17 of 123
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide (BLV)

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability,...

Invitation-only
Healthy
Drug: VG-3927
Drug: Placebo

This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy...

Enrolling
Healthy Participants
Drug: Placebo
Drug: PMN310

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in partic...

Enrolling
Healthy
Hepatic Insufficiency
Drug: LY3502970

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to g...

Enrolling
Healthy
Renal Insufficiency
Drug: LY3502970

The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with kidney problems compared t...

Enrolling
Healthy Volunteers
Renal Impairment
Drug: TAK-279

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic St...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: Tirzepatide

The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the cur...

Active, not recruiting
Healthy Volunteers
Drug: Risankizumab

PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesi...

Enrolling
Bunion
Drug: Ropivacaine

This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of B...

Enrolling
Obesity
Non-alcoholic Fatty Liver Disease
Drug: Placebo matching BI 3006337
Drug: BI 3006337
Status recently updated

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe...

Enrolling
Active, not recruiting
Pain
Drug: VX-548

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, b...

Not yet enrolling
Obesity
Drug: Placebo to DA-1726
Drug: DA-1726

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling
Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.

Enrolling
Obesity
Drug: AMG 786
Other: Placebo

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measur...

Enrolling
Chronic Hepatitis D Infection
Biological: Bulevirtide

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subj...

Enrolling
NON-ALCOHOLIC STEATOHEPATITIS
Drug: Sitagliptin
Drug: DA-1241 Placebo

Trial conditions

Renal Insufficiency (25 trials)
Liver Diseases (24 trials)
Fatty Liver (7 trials)
Non-alcoholic Fatty Live... (7 trials)
Diabetes Mellitus (6 trials)
Type 2 Diabetes Mellitus (6 trials)
Obesity (5 trials)
Hepatic Insufficiency (3 trials)
Liver Failure (3 trials)
Neuralgia (3 trials)

And 22 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems